News & Articles

Northway Biotech would like to announce that UAB Biotechpharma has successfully implemented the project “Biosimilar monoclonal antibody fragment synthesis in E. coli, manufacturing technology generation and capacity upscaling to 3000L”, which was financed according to the 2014-2020 European Union Investment Funds program, Priority No. 1 “Promotion of scientific research, experimental development and innovation”, No. J05-LVPA-K “Intelektas. Bendri mokslo – verslo projektai” invitation No. 3. Northway Biotech received EUR 3,9 million support, while the total project investment reached about EUR 15 million.

Northway Biotech would like to announce that UAB Biotechpharma has successfully implemented the project "Development of innovative technologies based on microbial biosynthesis and development of microbial biosynthesis R&D infrastructure" financed under the 2014-2020 European Union funds investment program Priority No. 1 "Promotion of scientific research, experimental development and innovation" No. J05-LVPA-K "Intelektas LT-2" invitation No. 1. For the implementation of the project, Northway Biotech received EUR 9,022,220.10 support from the European Union, while the total project investment reached about EUR 40 million.

Northway Biotechpharma would like to announce that UAB “Biotechpharma” has implemented the project „Development of biosimilar monoclonal antibody production technologies“ financed according to the Operational Programme for The European Union Funds Investments for 2014-2020, Priority No. 1 “Promotion of scientific researches, experimental development and innovation”, No. J05-LVPA-K “Intelektas. Bendri mokslo – verslo projektai” invitation No 1. “Biotechpharma” has received 2.119.828 EUR support from the European Union Funds for implementation of the project.

We would like to announce that on 2018-06-18 UAB Biotechnologinės farmacijos centras “Biotechpharma” and Public Institution Lithuanian Business Support Agency signed an agreement for the development of “Biosimilar monoclonal antibody fragment synthesis in E. coli, manufacturing technology generation and capacity upscaling to 3000L” project. This project is financed according to the 2014-2020 European Union Investment Funds program, Priority No. 1 “Promotion of scientific research, experimental development and innovation”, No. J05-LVPA-K “Intelektas. Bendri mokslo – verslo projektai” invitation No. 3. “Biotechpharma” will receive 3.984.837,68 EUR from the European Union Funds to support successful project implementation. Project implementation period is from 2018 till 2021.

Northway Biotechpharma would like to announce that UAB “Biotechpharma” has implemented the project “Creation of pegylated alpha 5 interferon”, financed according to the Operational Programme for The European Union Funds Investments for 2014-2020, Priority No. 1 “Promotion of scientific researches, experimental development and innovation”, No. J05-LVPA-K “Intelektas. Bendri mokslo – verslo projektai” invitation No 1. “Biotechpharma” has received 507.184,09 EUR support from the European Union Funds for implementation of the project.